Pyoderma Gangrenosum clinical trials
The registry lists 34 studies for Pyoderma Gangrenosum across more than 10 countries. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-09.
Status
- Completed
- 11
- Terminated
- 7
- Withdrawn
- 5
- Recruiting
- 4
- Not yet recruiting
- 4
- Status unknown
- 3
Phase
- Phase 2
- 17
- Phase 3
- 6
- Early Phase 1
- 2
- Phase 4
- 2
- Phase 1
- 1
Where
- United States
- 20
- Australia
- 5
- Canada
- 4
- Switzerland
- 4
- Japan
- 3
- France
- 3
Who runs them
Oregon Health and Science University (4) · XOMA (US) LLC (4) · AbbVie (2) · Ohio State University (2) · InflaRx GmbH (2) · Wake Forest University Health Sciences (2) · University of Zurich (2) · University Hospitals Cleveland Medical Center (1)
Studies
Recruiting first, then most recently updated. Showing 34 of 34 — search for more.
- Emerging Indications for Hyperbaric Oxygen TreatmentNot yet recruitingNCT07240649Phase 4
- A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma GangrenosumRecruitingNCT07337564Phase 21 country
- A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma GangrenosumRecruitingNCT06624670Phase 321 countries
- Topical Ruxolitinib in the Treatment of Adults With Pyoderma GangrenosumNot yet recruitingNCT07783412Phase 2
- Efficacy of Bimekizumab in Adults With Pyoderma GangrenosumNot yet recruitingNCT07767864Phase 21 country
- Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)RecruitingNCT06563323Phase 21 country
- A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma GangrenosumNot yet recruitingNCT07444684Phase 21 country
- A Real-World Registry of Chronic Wounds and UlcersRecruitingNCT022807331 country
- Spesolimab in Pyoderma GangrenosumTerminatedNCT06092216Phase 21 country
- Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumTerminatedNCT05964413Phase 310 countries
- A Novel Therapeutic Treatment of Pyoderma GangrenosumTerminatedNCT05120726Phase 41 country
- Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma GangrenosumWithdrawnNCT05984654Not applicable1 country
- A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)CompletedNCT047502131 country
- A Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumCompletedNCT01965613Phase 21 country
- Deucravacitinib in PGWithdrawnNCT05821374Early Phase 11 country
- Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)CompletedNCT04901325Phase 21 country
- An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumCompletedNCT03137160Phase 21 country
- Exploratory Study of IFX-1 in Patients With Pyoderma GangrenosumCompletedNCT03971643Phase 23 countries
- Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumCompletedNCT02733094Phase 1/21 country
- Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent PyodermaCompletedNCT04895566Early Phase 12 countries
- JAK-STAT Signaling Pathway in Pyoderma GangrenosumStatus unknownNCT04792957
- Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumWithdrawnNCT00730717Phase 21 country
- Efficacy and Safety of APD334 in Patients With Pyoderma GangrenosumTerminatedNCT03072953Phase 22 countries
- Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumWithdrawnNCT04274166Phase 2
- A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in JapanCompletedNCT03311464Phase 31 country
- Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumWithdrawnNCT00690846Phase 21 country
- Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma GangrenosumStatus unknownNCT036367371 country
- Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel DiseaseCompletedNCT00791557Not applicable1 country
- Canakinumab for Pyoderma GangrenosumCompletedNCT01302795Phase 21 country
- Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin DiseasesStatus unknownNCT019522751 country
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02326740Phase 33 countries
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02315417Phase 31 country
- A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedNCT02318914Phase 33 countries
- Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedNCT01882504Phase 21 country